Please assess the completion status of the following clinical trial:

Trial Title: Effect of Irvingia Gabonensis Administration on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients both sexes~* Age between 30 and 60 years~* Metabolic syndrome according IDF modified criteria~* Waist circumference: Men ≥90 cm, women ≥80 cm~And two of the following criteria:~* HDL-C: Men ≤40 mg/dL, women ≤50 mg/dL~* Fasting glucose ≥100 mg/dL~* Triglycerides ≥150 mg/dL~* Blood pressure ≥130/85 mmHg~* Informed consent signed~Exclusion Criteria:~* Women with confirmed or suspected pregnancy~* Women under lactation and/or puerperium~* Known hypersensibility to Irvingia gabonensis~* Physical impossibility for taking pills~* Known uncontrolled renal, hepatic, heart or thyroid disease~* Previous treatment for the metabolic syndrome components~* Body mass index ≥ 39.9 kg/m2~* Fasting glucose ≥126 mg/dL~* Triglycerides ≥ 500 mg/dL~* Total cholesterol ≥ 240 mg/dL~* LDL-C ≥190 mg/dL~* Blood pressure ≥140/90 mmHg

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Irvingia gabonensis (Type: EXPERIMENTAL): Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).